Literature DB >> 31981240

CCHE1 accelerated the initiation of oral squamous cell carcinoma through enhancing PAK2 expression by sponging miR-922.

Yongliang Wang1, Junjie Tong2, Haozhi Lin2, Lei Ma1, Yaoxiang Xu2,3.   

Abstract

BACKGROUND: Oral squamous cell carcinoma (OSCC) is a normal form of mouth cancer, comprising the majority of oral cancers. A large number of long non-coding RNAs (lncRNAs) have been reported due to their oncogenic function in cancers. Recent studies show that lncRNA CCHE1 is an oncogene in a wide range of cancers. Whether CCHE1 accelerates the progression of OSCC is still undiscovered.
METHODS: The qRT-PCR analysis was used to determine CCHE1, miR-922, and PAK2 expression levels. CCK8 and colony formation assays were applied to evaluate OSCC cell proliferative ability. Transwell assay was performed to investigate the capability of cell migration and invasion. Cell apoptosis was assessed by flow cytometry analysis. The distribution of CCHE1 in OSCC cells was confirmed via subcellular fractionation assay. Luciferase reporter assay was used to verify the connection between miR-922 and CCHE1 or PAK2.
RESULTS: qRT-PCR analysis identified the upregulation of CCHE1 in OSCC cells. Knockdown of CCHE1 curbed the proliferation, migration, and invasion and hastened the apoptosis in OSCC cell lines. Moreover, it was found that miR-922 could interact with CCHE1. Besides, PAK2 was identified as the target gene of miR-922 and its expression was negatively modulated by miR-922 and positively regulated by CCHE1. Restoration assay manifested that the suppressing influence of CCHE1 depletion on OSCC progression was rescued by amplified PAK2.
CONCLUSIONS: CCHE1 increases the expression of PAK2 to promote the progression of OSCC by competitively binding to miR-922 in OSCC cells.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CCHE1; PAK2; miR-922; oral squamous cell carcinoma

Year:  2020        PMID: 31981240     DOI: 10.1111/jop.12995

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  7 in total

Review 1.  Epigenetic and Transcriptomic Regulation Landscape in HPV+ Cancers: Biological and Clinical Implications.

Authors:  Rosario Castro-Oropeza; Patricia Piña-Sánchez
Journal:  Front Genet       Date:  2022-06-14       Impact factor: 4.772

Review 2.  The Role of Long Noncoding RNAs in Human Papillomavirus-associated Pathogenesis.

Authors:  Surendra Sharma; Karl Munger
Journal:  Pathogens       Date:  2020-04-15

Review 3.  Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.

Authors:  Deniz Mortazavi; Behnoush Sohrabi; Meysam Mosallaei; Ziba Nariman-Saleh-Fam; Milad Bastami; Yaser Mansoori; Abdolreza Daraei; Sepideh Zununi Vahed; Shadan Navid; Zahra Saadatian; Tannaz Jamialahmadi; Yong Teng; Amirhossein Sahebkar
Journal:  J Oncol       Date:  2022-01-11       Impact factor: 4.375

Review 4.  Long Non-Coding RNAs as Functional Codes for Oral Cancer: Translational Potential, Progress and Promises.

Authors:  Cing-Syuan Lei; Hsing-Jien Kung; Jing-Wen Shih
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

5.  Cervical carcinoma high-expressed long non-coding RNA 1 promotes papillary thyroid carcinoma cell proliferation and invasion.

Authors:  Ping Shi; Yan Liu; Mingzeng Zhang; Jianwang Yang; Shanghua Jing; Dongqiang Yang; Fei Liu; Yanzhao Wu; Huijing Shi; Cuizhi Geng
Journal:  Transl Cancer Res       Date:  2021-09       Impact factor: 1.241

6.  MicroRNA-194-5p Attenuates Doxorubicin-Induced Cardiomyocyte Apoptosis and Endoplasmic Reticulum Stress by Targeting P21-Activated Kinase 2.

Authors:  Hongge Fa; Dandan Xiao; Wenguang Chang; Lin Ding; Lanting Yang; Yu Wang; Mengyu Wang; Jianxun Wang
Journal:  Front Cardiovasc Med       Date:  2022-03-07

7.  Cancer-released exosomal circular RNA circ_0008717 promotes cell tumorigenicity through microRNA-1287-5p/P21-activated kinase 2 (PAK2) axis in non-small cell lung cancer.

Authors:  Huimin Wang; Zhiqin Tang; Jihui Duan; Chunlei Zhou; Ke Xu; Hong Mu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.